Cargando…
Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485970/ https://www.ncbi.nlm.nih.gov/pubmed/34599382 http://dx.doi.org/10.1007/s00277-021-04666-x |
| _version_ | 1784577642132930560 |
|---|---|
| author | Saito, Kei Ichikawa, Satoshi Hatta, Shunsuke Katsuoka, Yuna Harigae, Hideo Izumi, Tohru |
| author_facet | Saito, Kei Ichikawa, Satoshi Hatta, Shunsuke Katsuoka, Yuna Harigae, Hideo Izumi, Tohru |
| author_sort | Saito, Kei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8485970 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84859702021-10-04 Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination Saito, Kei Ichikawa, Satoshi Hatta, Shunsuke Katsuoka, Yuna Harigae, Hideo Izumi, Tohru Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2021-10-01 2022 /pmc/articles/PMC8485970/ /pubmed/34599382 http://dx.doi.org/10.1007/s00277-021-04666-x Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Saito, Kei Ichikawa, Satoshi Hatta, Shunsuke Katsuoka, Yuna Harigae, Hideo Izumi, Tohru Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title | Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title_full | Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title_fullStr | Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title_full_unstemmed | Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title_short | Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination |
| title_sort | vincristine therapy for severe and refractory immune thrombocytopenia following covid-19 vaccination |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485970/ https://www.ncbi.nlm.nih.gov/pubmed/34599382 http://dx.doi.org/10.1007/s00277-021-04666-x |
| work_keys_str_mv | AT saitokei vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination AT ichikawasatoshi vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination AT hattashunsuke vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination AT katsuokayuna vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination AT harigaehideo vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination AT izumitohru vincristinetherapyforsevereandrefractoryimmunethrombocytopeniafollowingcovid19vaccination |